In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.
about
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalClinical pharmacokinetics of oral controlled-release 5-fluorocytosineAntifungal susceptibility testing: practical aspects and current challenges.Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.Has antifungal susceptibility testing come of age?In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effectOral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.Antifungal pharmacokinetics and pharmacodynamicsNontoxic antimicrobials that evade drug resistance.Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosingIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Antifungal therapeutic drug monitoring: established and emerging indications.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Current concepts in antifungal pharmacology.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations.Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.Therapeutic drug monitoring of antimicrobials.Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.Antifungal drugs: predicting clinical efficacy with pharmacodynamics.Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy.
P2860
Q27012487-59AF4737-16FC-4025-8F20-56CF5CA37A1EQ33676182-26D13836-CF2E-49D2-8DAE-3E057285C1D0Q33975757-CC351032-4A51-4C70-80BF-D950254EA1C6Q34077069-E645DE79-12E6-41AB-B872-6DC60A9F3201Q34142406-5D66994D-D2E0-4417-BA0B-246A298BD880Q34301547-CAF85BC9-60DF-4D56-A01C-A55620296610Q34335230-71178DC5-BACB-4648-86B0-CF8EB5900AE7Q34881309-D430568C-96C1-41A9-9310-E87520654E54Q34923038-AEE6DDDA-7FCE-45C8-B8AE-6BD05558B739Q35091285-E7AC32DE-39B7-440B-A4A2-4BE068CCB5B2Q35127913-73FE6F39-B7E6-4A0B-B49A-80F8D28EB3BEQ35647796-D6C94E5C-B21B-4C74-8990-D1D0FD26DD8BQ35663841-D11B94D8-2613-4A6A-86FF-FCFA272E4EC1Q35756422-8D1ECCED-B2FA-49FC-9D82-762C0DF7335BQ36094962-30BE19C3-17E5-4C41-ABA7-CB83F04D1302Q36425025-17C17943-F275-41EE-845B-89CFEB9BF702Q36932989-F75DDC91-7D1D-4C3A-BA30-A7F4EEDDE423Q37310029-63ED360D-A96C-49BF-B2FB-F1687059D847Q37688257-F0D4DBFD-F7CA-4528-B1B0-B1018D1D4BEBQ37908856-F9F41947-BAE8-4980-891A-53F5C790F6ADQ38193337-DC69E1B2-5249-48CF-8F6B-D1842F0B49F1Q38790740-DE3A852A-0D39-4B0F-B284-160EC0E48ABCQ38919690-D1DCD9E0-8B35-40AF-A933-D78B101088B6Q39686543-77D4E569-D092-41F7-BBE8-CB72292EDE72Q40330676-F849FD3F-DBD6-4CEE-ADD2-B8A502C1A385Q40915627-3A1E5671-5BA7-4AB0-BF67-F669A87E355EQ40916536-A8840DFA-9A12-4F0B-9778-19C561C301BBQ42723597-9B66D50E-4CD8-425E-9B3B-EE757F9362B1Q48893820-D774E9ED-6938-48B7-B19B-EF02DBBFFEE7
P2860
In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vivo characterization of th ...... isseminated candidiasis model.
@ast
In vivo characterization of th ...... isseminated candidiasis model.
@en
type
label
In vivo characterization of th ...... isseminated candidiasis model.
@ast
In vivo characterization of th ...... isseminated candidiasis model.
@en
prefLabel
In vivo characterization of th ...... isseminated candidiasis model.
@ast
In vivo characterization of th ...... isseminated candidiasis model.
@en
P2860
P1476
In vivo characterization of th ...... isseminated candidiasis model.
@en
P2093
P2860
P304
P356
10.1128/AAC.44.4.938-942.2000
P407
P577
2000-04-01T00:00:00Z